Treatment of multiple sclerosis with human beta interferon.
Treatment of multiple sclerosis with human beta interferon.
复制标题
用人β干扰素治疗多发性硬化症。
DOI：
--
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
D. Goodin
中科院分区：
文献类型：
--
作者：
D. Goodin
本手稿采用循证方法来审查和分析证据，使用人β干扰素治疗MS。人β干扰素调节许多生物学过程被认为是参与MS的发展。β干扰素是一个分泌蛋白大家族的成员，参与生物体防御病毒感染、细胞生长调节和免疫应答的调节。β-干扰素在复发-缓解型和继发性进展型MS中的治疗功效已在几项临床试验中确立，并且证据表明β-干扰素的每周总剂量和/或β-干扰素给药频率是其临床使用的重要因素。我们对干扰素在健康和MS发病机制中的物理和生物学作用的理解不断加深，将推动MS未来治疗的发展。
The present manuscript uses an evidence-based approach to review and analyse evidence for the use of human beta interferon in the treatment of MS. Human beta interferon modulates many of the biological processes believed to be involved in MS development. Beta interferon is a member of a large family of secreted proteins that are involved in an organisms defence against viral infections, cell growth regulation and in modulation of immune response. The therapeutic efficacy of beta interferon in relapsing-remitting and secondary progressive MS has been established in several clinical trials, and evidence indicates that the total weekly dosage of beta interferon and/or the frequency of beta interferon administration are important factors in its clinical use. Future therapeutic developments in MS will be fuelled by our increasing understanding of the physical and biological roles of the interferons, in health and in MS pathogenesis.